In addition, it was shown that galunisertib in combination with anti-CTLA4 therapy suppresses both primary melanoma tumor growth as well as metastases in a physiological relevant trangenic melanoma model (Hanks et al. [50]). Here, CTLA4 is linked to neoplasm.